Difference between revisions of "Part:BBa K5237000"
Line 1: | Line 1: | ||
− | |||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K5237000</partinfo> | <partinfo>BBa_K5237000</partinfo> | ||
Line 27: | Line 26: | ||
padding: 5px; | padding: 5px; | ||
} | } | ||
+ | |||
.thumbcaption { | .thumbcaption { | ||
− | + | text-align: justify !important; | |
− | + | } | |
− | a[href ^="https://"],.link-https { | + | a[href ^="https://"], |
+ | .link-https { | ||
background: none !important; | background: none !important; | ||
− | padding-right:0px !important; | + | padding-right: 0px !important; |
− | } | + | } |
− | + | ||
</style> | </style> | ||
+ | |||
<body> | <body> | ||
− | <!-- Part summary --> | + | <!-- Part summary --> |
− | <section id="1"> | + | <section id="1"> |
− | <h1>fgRNA Entryvector MbCas12a-SpCas9</h1> | + | <h1>fgRNA Entryvector MbCas12a-SpCas9</h1> |
− | <p> | + | <p> |
− | This part integrates the crRNA of MbCas12a (BBa_K5237206) and the sgRNA of SpCas9 (BBa_K5237209) into a single fusion | + | This part integrates the crRNA of MbCas12a (BBa_K5237206) and the sgRNA of SpCas9 (BBa_K5237209) into a single |
− | guide RNA (fgRNA). The fgRNA is functional meaning that the MbCas12a (<a href="https://parts.igem.org/Part:BBa_K5237001">BBa_K5237000</a>), | + | fusion |
− | SpCas9 (<a href="https://parts.igem.org/Part:BBa_K5237002">BBa_K5237002</a>) and the Cas-Staple (<a href="https://parts.igem.org/Part:BBa_K5237003">BBa_K5237003</a>) | + | guide RNA (fgRNA). The fgRNA is functional meaning that the MbCas12a (<a |
− | can utilize the fgRNA to target two loci simultaneously. The fgRNA also works with the catalyitcally inactive versions. | + | href="https://parts.igem.org/Part:BBa_K5237001">BBa_K5237000</a>), |
+ | SpCas9 (<a href="https://parts.igem.org/Part:BBa_K5237002">BBa_K5237002</a>) and the Cas-Staple (<a | ||
+ | href="https://parts.igem.org/Part:BBa_K5237003">BBa_K5237003</a>) | ||
+ | can utilize the fgRNA to target two loci simultaneously. The fgRNA also works with the catalyitcally inactive | ||
+ | versions. | ||
We could show editing with the active version and induced proximity of to loci with the inactive version. | We could show editing with the active version and induced proximity of to loci with the inactive version. | ||
</p> | </p> | ||
− | <p> </p> | + | <p> </p> |
− | </section> | + | </section> |
− | <div class="toc" id="toc"> | + | <div class="toc" id="toc"> |
− | <div id="toctitle"> | + | <div id="toctitle"> |
− | <h1>Contents</h1> | + | <h1>Contents</h1> |
− | </div> | + | </div> |
− | <ul> | + | <ul> |
− | <li class="toclevel-1 tocsection-1"><a href="#1"><span class="tocnumber">1</span> <span class="toctext">Sequence | + | <li class="toclevel-1 tocsection-1"><a href="#1"><span class="tocnumber">1</span> <span class="toctext">Sequence |
overview</span></a> | overview</span></a> | ||
− | </li> | + | </li> |
− | <li class="toclevel-1 tocsection-2"><a href="#2"><span class="tocnumber">2</span> <span class="toctext">Usage and | + | <li class="toclevel-1 tocsection-2"><a href="#2"><span class="tocnumber">2</span> <span class="toctext">Usage and |
Biology</span></a> | Biology</span></a> | ||
− | <ul> | + | <ul> |
− | <li class="toclevel-2 tocsection-2.1"> | + | <li class="toclevel-2 tocsection-2.1"> |
− | <a href="#2.1"><span class="tocnumber">2.1</span> <span class="toctext">Discovery and Mechanism of CRISPR/Cas9</span></a> | + | <a href="#2.1"><span class="tocnumber">2.1</span> <span class="toctext">Discovery and Mechanism of |
− | </li> | + | CRISPR/Cas9</span></a> |
− | <li class="toclevel-2 tocsection-2.2"> | + | </li> |
− | <a href="#2.2"><span class="tocnumber">2.2</span> <span class="toctext">Differences between Cas9 and Cas12a</span></a></li> | + | <li class="toclevel-2 tocsection-2.2"> |
− | <li class="toclevel-2 tocsection-2.3"> | + | <a href="#2.2"><span class="tocnumber">2.2</span> <span class="toctext">Differences between Cas9 and |
− | <a href="#2.3"><span class="tocnumber">2.3</span> <span class="toctext">Dead Cas Proteins and their Application</span></a></li> | + | Cas12a</span></a> |
− | <li class="toclevel-2 tocsection-2.4"> | + | </li> |
− | <a href="#2.4"><span class="tocnumber">2.4</span> <span class="toctext">fgRNA and CHyMErA System</span></a></li> | + | <li class="toclevel-2 tocsection-2.3"> |
− | </ul> | + | <a href="#2.3"><span class="tocnumber">2.3</span> <span class="toctext">Dead Cas Proteins and their |
− | </li> | + | Application</span></a> |
− | <li class="toclevel-1 tocsetction-3"><a href="#3"><span class="tocnumber">3</span> <span class="toctext">Assembly | + | </li> |
+ | <li class="toclevel-2 tocsection-2.4"> | ||
+ | <a href="#2.4"><span class="tocnumber">2.4</span> <span class="toctext">fgRNA and CHyMErA System</span></a> | ||
+ | </li> | ||
+ | </ul> | ||
+ | </li> | ||
+ | <li class="toclevel-1 tocsetction-3"><a href="#3"><span class="tocnumber">3</span> <span class="toctext">Assembly | ||
and part evolution</span></a> | and part evolution</span></a> | ||
− | </li> | + | </li> |
− | <li class="toclevel-1 tocsection-4"><a href="#4"><span class="tocnumber">4</span> <span class="toctext">Results</span></a> | + | <li class="toclevel-1 tocsection-4"><a href="#4"><span class="tocnumber">4</span> <span |
− | <ul> | + | class="toctext">Results</span></a> |
− | <li class="toclevel-2 tocsection-4.1"> | + | <ul> |
− | <a href="#4.1"><span class="tocnumber">4.1</span> <span class="toctext">Editing endogenous loci with fgRNAs</span></a></li> | + | <li class="toclevel-2 tocsection-4.1"> |
− | <li class="toclevel-2 tocsection-4.2"> | + | <a href="#4.1"><span class="tocnumber">4.1</span> <span class="toctext">Editing endogenous loci with |
− | <a href="#4.2"><span class="tocnumber">4.2</span> <span class="toctext">Proximity assay with inactive Cas proteins</span></a></li> | + | fgRNAs</span></a> |
− | <li class="toclevel-2 tocsection-4.3"> | + | </li> |
− | <a href="#4.3"><span class="tocnumber">4.3</span> <span class="toctext">The Inclusion of a Linker Does Not Lower Editing Rates</span></a></li> | + | <li class="toclevel-2 tocsection-4.2"> |
− | <li class="toclevel-2 tocsection-4.4"> | + | <a href="#4.2"><span class="tocnumber">4.2</span> <span class="toctext">Proximity assay with inactive Cas |
− | <a href="#4.4"><span class="tocnumber">4.4</span> <span class="toctext">fgRNAs can be Used for CRISPRa</span></a></li> | + | proteins</span></a> |
− | <li class="toclevel-2 tocsection-4.5"> | + | </li> |
− | <a href="#4.5"><span class="tocnumber">4.5</span> <span class="toctext">Stapling Two DNA Strands Together Using fgRNAs</span></a></li> | + | <li class="toclevel-2 tocsection-4.3"> |
− | </ul> | + | <a href="#4.3"><span class="tocnumber">4.3</span> <span class="toctext">The Inclusion of a Linker Does Not |
− | </li> | + | Lower Editing Rates</span></a> |
− | <li class="toclevel-1 tocsection-8"><a href="#5"><span class="tocnumber">5</span> <span class="toctext">References</span></a> | + | </li> |
− | </li> | + | <li class="toclevel-2 tocsection-4.4"> |
− | </ul> | + | <a href="#4.4"><span class="tocnumber">4.4</span> <span class="toctext">fgRNAs can be Used for |
− | </div> | + | CRISPRa</span></a> |
− | <section><p><br/><br/></p> | + | </li> |
− | <font size="5"><b>The PICasSO Toolbox </b> </font> | + | <li class="toclevel-2 tocsection-4.5"> |
− | <div class="thumb" style="margin-top:10px;"></div> | + | <a href="#4.5"><span class="tocnumber">4.5</span> <span class="toctext">Stapling Two DNA Strands Together |
− | <div class="thumbinner" style="width:550px"><img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/registry-part-collection-engineering-cycle-example-overview.svg" style="width:99%;"/> | + | Using fgRNAs</span></a> |
− | <div class="thumbcaption"> | + | </li> |
− | <i><b>Figure 1: How our part collection can be used to engineer new staples</b></i> | + | </ul> |
− | </div> | + | </li> |
− | </div> | + | <li class="toclevel-1 tocsection-8"><a href="#5"><span class="tocnumber">5</span> <span |
+ | class="toctext">References</span></a> | ||
+ | </li> | ||
+ | </ul> | ||
+ | </div> | ||
+ | <section> | ||
+ | <p><br /><br /></p> | ||
+ | <font size="5"><b>The PICasSO Toolbox </b> </font> | ||
+ | <div class="thumb" style="margin-top:10px;"></div> | ||
+ | <div class="thumbinner" style="width:550px"><img alt="" class="thumbimage" | ||
+ | src="https://static.igem.wiki/teams/5237/wetlab-results/registry-part-collection-engineering-cycle-example-overview.svg" | ||
+ | style="width:99%;" /> | ||
+ | <div class="thumbcaption"> | ||
+ | <i><b>Figure 1: How our part collection can be used to engineer new staples</b></i> | ||
+ | </div> | ||
+ | </div> | ||
− | <p> | + | <p> |
− | <br/> | + | <br /> |
− | Next to the well-studied linear DNA sequence, the 3D spatial organization of DNA plays a crucial role in gene regulation, | + | Next to the well-studied linear DNA sequence, the 3D spatial organization of DNA plays a crucial role in gene |
− | cell fate, disease development and more. However, the tools to precisely manipulate this genomic architecture remain limited, rendering it challenging to explore the full potential of the | + | regulation, |
+ | cell fate, disease development and more. However, the tools to precisely manipulate this genomic architecture | ||
+ | remain limited, rendering it challenging to explore the full potential of the | ||
3D genome in synthetic biology. We - iGEM Team Heidelberg 2024 - have developed PICasSO, a powerful molecular | 3D genome in synthetic biology. We - iGEM Team Heidelberg 2024 - have developed PICasSO, a powerful molecular | ||
toolbox based on various DNA-binding proteins to address this issue. | toolbox based on various DNA-binding proteins to address this issue. | ||
</p> | </p> | ||
− | <p> | + | <p> |
The <b>PICasSO</b> part collection offers a comprehensive, modular platform for precise manipulation and | The <b>PICasSO</b> part collection offers a comprehensive, modular platform for precise manipulation and | ||
re-programming | re-programming | ||
Line 119: | Line 147: | ||
parts crucial for testing every step of the cycle (design, build, test, learn) when engineering new parts. | parts crucial for testing every step of the cycle (design, build, test, learn) when engineering new parts. | ||
</p> | </p> | ||
− | <p>At its heart, the PICasSO part collection consists of three categories. <br/><b>(i)</b> Our <b>DNA-binding proteins</b> | + | <p>At its heart, the PICasSO part collection consists of three categories. <br /><b>(i)</b> Our <b>DNA-binding |
+ | proteins</b> | ||
include our | include our | ||
finalized enhancer hijacking Cas staple as well as half staples that can be used by scientists to compose entirely | finalized enhancer hijacking Cas staple as well as half staples that can be used by scientists to compose entirely | ||
new Cas staples in the future. We also include our Simple staples that serve as controls for successful stapling | new Cas staples in the future. We also include our Simple staples that serve as controls for successful stapling | ||
− | and can be further engineered to create alternative, simpler and more compact staples. <br/> | + | and can be further engineered to create alternative, simpler and more compact staples. <br /> |
− | <b>(ii)</b> As <b>functional elements</b>, we list additional parts that enhance the functionality of our Cas and Basic staples. These | + | <b>(ii)</b> As <b>functional elements</b>, we list additional parts that enhance the functionality of our Cas and |
+ | Basic staples. These | ||
consist of | consist of | ||
protease-cleavable peptide linkers and inteins that allow condition-specific, dynamic stapling <i>in vivo</i>. | protease-cleavable peptide linkers and inteins that allow condition-specific, dynamic stapling <i>in vivo</i>. | ||
− | Besides staple functionality, we also include the parts to enable the efficient delivery of PICasSO's constructs with our | + | Besides staple functionality, we also include the parts to enable the efficient delivery of PICasSO's constructs |
− | interkingdom conjugation system. <br/> | + | with our |
− | <b>(iii)</b> As the final category of our collection, we provide parts that support the use of our <b>custom readout | + | interkingdom conjugation system. <br /> |
+ | <b>(iii)</b> As the final category of our collection, we provide parts that support the use of our <b>custom | ||
+ | readout | ||
systems</b>. These include components of our established FRET-based proximity assay system, enabling users to | systems</b>. These include components of our established FRET-based proximity assay system, enabling users to | ||
confirm | confirm | ||
accurate stapling. Additionally, we offer a complementary, application-oriented testing system for functional | accurate stapling. Additionally, we offer a complementary, application-oriented testing system for functional | ||
− | readouts via a luciferase reporter, which allows for straightforward experimental simulation of enhancer hijacking in mammalian cells. | + | readouts via a luciferase reporter, which allows for straightforward experimental simulation of enhancer hijacking |
+ | in mammalian cells. | ||
</p> | </p> | ||
− | <p> | + | <p> |
− | The following table gives a comprehensive overview of all parts in our PICasSO toolbox. <mark style="background-color: #FFD700; color: black;">The highlighted parts showed | + | The following table gives a comprehensive overview of all parts in our PICasSO toolbox. <mark |
− | + | style="background-color: #FFD700; color: black;">The highlighted parts showed | |
+ | exceptional performance as described on our iGEM wiki and can serve as a reference.</mark> The other parts in | ||
+ | the | ||
collection are versatile building blocks designed to provide future iGEMers with the flexibility to engineer their | collection are versatile building blocks designed to provide future iGEMers with the flexibility to engineer their | ||
− | own custom Cas staples, enabling further optimization and innovation.<br/> | + | own custom Cas staples, enabling further optimization and innovation.<br /> |
− | </p> | + | </p> |
− | <p> | + | <p> |
− | <font size="4"><b>Our part collection includes:</b></font><br/> | + | <font size="4"><b>Our part collection includes:</b></font><br /> |
− | </p> | + | </p> |
− | <table style="width: 90%; padding-right:10px;"> | + | <table style="width: 90%; padding-right:10px;"> |
− | <td align="left" colspan="3"><b>DNA-binding proteins: </b> | + | <td align="left" colspan="3"><b>DNA-binding proteins: </b> |
The building blocks for engineering of custom staples for DNA-DNA interactions with a modular system ensuring | The building blocks for engineering of custom staples for DNA-DNA interactions with a modular system ensuring | ||
easy assembly.</td> | easy assembly.</td> | ||
− | <tbody> | + | <tbody> |
− | <tr bgcolor="#FFD700"> | + | <tr bgcolor="#FFD700"> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237000" target="_blank">BBa_K5237000</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237000" target="_blank">BBa_K5237000</a></td> |
− | <td>fgRNA Entry vector MbCas12a-SpCas9</td> | + | <td>fgRNA Entry vector MbCas12a-SpCas9</td> |
− | <td>Entryvector for simple fgRNA cloning via SapI</td> | + | <td>Entryvector for simple fgRNA cloning via SapI</td> |
− | </tr> | + | </tr> |
− | <tr bgcolor="#FFD700"> | + | <tr bgcolor="#FFD700"> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237001" target="_blank">BBa_K5237001</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237001" target="_blank">BBa_K5237001</a></td> |
− | <td>Staple subunit: dMbCas12a-Nucleoplasmin NLS</td> | + | <td>Staple subunit: dMbCas12a-Nucleoplasmin NLS</td> |
− | <td>Staple subunit that can be combined with sgRNA or fgRNA and dCas9 to form a functional staple</td> | + | <td>Staple subunit that can be combined with sgRNA or fgRNA and dCas9 to form a functional staple</td> |
− | </tr> | + | </tr> |
− | <tr bgcolor="#FFD700"> | + | <tr bgcolor="#FFD700"> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237002" target="_blank">BBa_K5237002</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237002" target="_blank">BBa_K5237002</a></td> |
− | <td>Staple subunit: SV40 NLS-dSpCas9-SV40 NLS</td> | + | <td>Staple subunit: SV40 NLS-dSpCas9-SV40 NLS</td> |
− | <td>Staple subunit that can be combined witha sgRNA or fgRNA and dCas12avto form a functional staple | + | <td>Staple subunit that can be combined witha sgRNA or fgRNA and dCas12avto form a functional staple |
</td> | </td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237003" target="_blank">BBa_K5237003</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237003" target="_blank">BBa_K5237003</a></td> |
− | <td>Cas Staple: SV40 NLS-dMbCas12a-dSpCas9-Nucleoplasmin NLS</td> | + | <td>Cas Staple: SV40 NLS-dMbCas12a-dSpCas9-Nucleoplasmin NLS</td> |
− | <td>Functional Cas staple that can be combined with sgRNA or fgRNA to bring two DNA strands into | + | <td>Functional Cas staple that can be combined with sgRNA or fgRNA to bring two DNA strands into close |
+ | proximity | ||
</td> | </td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237004" target="_blank">BBa_K5237004</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237004" target="_blank">BBa_K5237004</a></td> |
− | <td>Staple subunit: Oct1-DBD</td> | + | <td>Staple subunit: Oct1-DBD</td> |
− | <td>Staple subunit that can be combined to form a functional staple, for example with TetR.<br/> | + | <td>Staple subunit that can be combined to form a functional staple, for example with TetR.<br /> |
Can also be combined with a fluorescent protein as part of the FRET proximity assay</td> | Can also be combined with a fluorescent protein as part of the FRET proximity assay</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237005" target="_blank">BBa_K5237005</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237005" target="_blank">BBa_K5237005</a></td> |
− | <td>Staple subunit: TetR</td> | + | <td>Staple subunit: TetR</td> |
− | <td>Staple subunit that can be combined to form a functional staple, for example with Oct1.<br/> | + | <td>Staple subunit that can be combined to form a functional staple, for example with Oct1.<br /> |
Can also be combined with a fluorescent protein as part of the FRET proximity assay</td> | Can also be combined with a fluorescent protein as part of the FRET proximity assay</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237006" target="_blank">BBa_K5237006</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237006" target="_blank">BBa_K5237006</a></td> |
− | <td>Simple staple: TetR-Oct1</td> | + | <td>Simple staple: TetR-Oct1</td> |
− | <td>Functional staple that can be used to bring two DNA strands in close proximity</td> | + | <td>Functional staple that can be used to bring two DNA strands in close proximity</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237007" target="_blank">BBa_K5237007</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237007" target="_blank">BBa_K5237007</a></td> |
− | <td>Staple subunit: GCN4</td> | + | <td>Staple subunit: GCN4</td> |
− | <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td> | + | <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237008" target="_blank">BBa_K5237008</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237008" target="_blank">BBa_K5237008</a></td> |
− | <td>Staple subunit: rGCN4</td> | + | <td>Staple subunit: rGCN4</td> |
− | <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td> | + | <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237009" target="_blank">BBa_K5237009</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237009" target="_blank">BBa_K5237009</a></td> |
− | <td>Mini staple: bGCN4</td> | + | <td>Mini staple: bGCN4</td> |
− | <td> | + | <td> |
Assembled staple with minimal size that can be further engineered</td> | Assembled staple with minimal size that can be further engineered</td> | ||
− | </tr> | + | </tr> |
− | </tbody> | + | </tbody> |
− | <td align="left" colspan="3"><b>Functional elements: </b> | + | <td align="left" colspan="3"><b>Functional elements: </b> |
Protease-cleavable peptide linkers and inteins are used to control and modify staples for further optimization | Protease-cleavable peptide linkers and inteins are used to control and modify staples for further optimization | ||
for custom applications</td> | for custom applications</td> | ||
− | <tbody> | + | <tbody> |
− | <tr bgcolor="#FFD700"> | + | <tr bgcolor="#FFD700"> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237010" target="_blank">BBa_K5237010</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237010" target="_blank">BBa_K5237010</a></td> |
− | <td>Cathepsin B-cleavable Linker: GFLG</td> | + | <td>Cathepsin B-cleavable Linker: GFLG</td> |
− | <td>Cathepsin B-cleavable peptide linker that can be used to combine two staple subunits to make responsive | + | <td>Cathepsin B-cleavable peptide linker that can be used to combine two staple subunits to make responsive |
staples</td> | staples</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237011" target="_blank">BBa_K5237011</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237011" target="_blank">BBa_K5237011</a></td> |
− | <td>Cathepsin B Expression Cassette</td> | + | <td>Cathepsin B Expression Cassette</td> |
− | <td>Expression Cassette for the overexpression of cathepsin B</td> | + | <td>Expression Cassette for the overexpression of cathepsin B</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237012" target="_blank">BBa_K5237012</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237012" target="_blank">BBa_K5237012</a></td> |
− | <td>Caged NpuN Intein</td> | + | <td>Caged NpuN Intein</td> |
− | <td>A caged NpuN split intein fragment that undergoes protein <i>trans</i>-splicing after protease activation. Can be used to create functionalized staples | + | <td>A caged NpuN split intein fragment that undergoes protein <i>trans</i>-splicing after protease activation. |
+ | Can be used to create functionalized staples | ||
units</td> | units</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237013" target="_blank">BBa_K5237013</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237013" target="_blank">BBa_K5237013</a></td> |
− | <td>Caged NpuC Intein</td> | + | <td>Caged NpuC Intein</td> |
− | <td>A caged NpuC split intein fragment that undergoes protein <i>trans</i>-splicing after protease activation. Can be used to create functionalized staples | + | <td>A caged NpuC split intein fragment that undergoes protein <i>trans</i>-splicing after protease activation. |
+ | Can be used to create functionalized staples | ||
units</td> | units</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237014" target="_blank">BBa_K5237014</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237014" target="_blank">BBa_K5237014</a></td> |
− | <td>fgRNA processing casette</td> | + | <td>fgRNA processing casette</td> |
− | <td>Processing casette to produce multiple fgRNAs from one transcript, that can be used for multiplexed 3D genome reprograming</td> | + | <td>Processing casette to produce multiple fgRNAs from one transcript, that can be used for multiplexed 3D |
− | </tr> | + | genome reprograming</td> |
− | <tr> | + | </tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237015" target="_blank">BBa_K5237015</a></td> | + | <tr> |
− | <td>Intimin anti-EGFR Nanobody</td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237015" target="_blank">BBa_K5237015</a></td> |
− | <td>Interkindom conjugation between bacteria and mammalian cells, as alternative delivery tool for large | + | <td>Intimin anti-EGFR Nanobody</td> |
+ | <td>Interkindom conjugation between bacteria and mammalian cells, as alternative delivery tool for large | ||
constructs</td> | constructs</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K4643003" target="_blank">BBa_K4643003</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K4643003" target="_blank">BBa_K4643003</a></td> |
− | <td>incP origin of transfer</td> | + | <td>incP origin of transfer</td> |
− | <td>Origin of transfer that can be cloned into the plasmid vector and used for conjugation as a means of delivery</td> | + | <td>Origin of transfer that can be cloned into the plasmid vector and used for conjugation as a means of |
− | </tr> | + | delivery</td> |
− | </tbody> | + | </tr> |
− | <td align="left" colspan="3"><b>Readout Systems: </b> | + | </tbody> |
+ | <td align="left" colspan="3"><b>Readout Systems: </b> | ||
FRET and enhancer recruitment to measure proximity of stapled DNA in bacterial and mammalian living cells | FRET and enhancer recruitment to measure proximity of stapled DNA in bacterial and mammalian living cells | ||
enabling swift testing and easy development for new systems</td> | enabling swift testing and easy development for new systems</td> | ||
− | <tbody> | + | <tbody> |
− | <tr bgcolor="#FFD700"> | + | <tr bgcolor="#FFD700"> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237016" target="_blank">BBa_K5237016</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237016" target="_blank">BBa_K5237016</a></td> |
− | <td>FRET-Donor: mNeonGreen-Oct1</td> | + | <td>FRET-Donor: mNeonGreen-Oct1</td> |
− | <td>FRET Donor-Fluorpohore fused to Oct1-DBD that binds to the Oct1 binding cassette. Can be used to visualize DNA-DNA | + | <td>FRET Donor-Fluorpohore fused to Oct1-DBD that binds to the Oct1 binding cassette. Can be used to visualize |
+ | DNA-DNA | ||
proximity</td> | proximity</td> | ||
− | </tr> | + | </tr> |
− | <tr bgcolor="#FFD700"> | + | <tr bgcolor="#FFD700"> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237017" target="_blank">BBa_K5237017</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237017" target="_blank">BBa_K5237017</a></td> |
− | <td>FRET-Acceptor: TetR-mScarlet-I</td> | + | <td>FRET-Acceptor: TetR-mScarlet-I</td> |
− | <td>Acceptor part for the FRET assay binding the TetR binding cassette. Can be used to visualize DNA-DNA | + | <td>Acceptor part for the FRET assay binding the TetR binding cassette. Can be used to visualize DNA-DNA |
proximity</td> | proximity</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237018" target="_blank">BBa_K5237018</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237018" target="_blank">BBa_K5237018</a></td> |
− | <td>Oct1 Binding Casette</td> | + | <td>Oct1 Binding Casette</td> |
− | <td>DNA sequence containing 12 Oct1 binding motifs, compatible with various assays such as the FRET | + | <td>DNA sequence containing 12 Oct1 binding motifs, compatible with various assays such as the FRET |
proximity assay</td> | proximity assay</td> | ||
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237019" target="_blank">BBa_K5237019</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237019" target="_blank">BBa_K5237019</a></td> |
− | <td>TetR Binding Cassette</td> | + | <td>TetR Binding Cassette</td> |
− | <td>DNA sequence containing 12 Oct1 binding motifs, can be used for different assays such as the FRET | + | <td>DNA sequence containing 12 Oct1 binding motifs, can be used for different assays such as the FRET |
proximity assay</td> | proximity assay</td> | ||
− | </tr> | + | </tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237020" target="_blank">BBa_K5237020</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237020" target="_blank">BBa_K5237020</a></td> |
− | <td>Cathepsin B-Cleavable Trans-Activator: NLS-Gal4-GFLG-VP64</td> | + | <td>Cathepsin B-Cleavable Trans-Activator: NLS-Gal4-GFLG-VP64</td> |
− | <td>Readout system that responds to protease activity. It was used to test cathepsin B-cleavable linker</td> | + | <td>Readout system that responds to protease activity. It was used to test cathepsin B-cleavable linker</td> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237021" target="_blank">BBa_K5237021</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237021" target="_blank">BBa_K5237021</a></td> |
− | <td>NLS-Gal4-VP64</td> | + | <td>NLS-Gal4-VP64</td> |
− | <td>Trans-activating enhancer, that can be used to simulate enhancer hijacking</td> | + | <td>Trans-activating enhancer, that can be used to simulate enhancer hijacking</td> |
− | </tr> | + | </tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237022" target="_blank">BBa_K5237022</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237022" target="_blank">BBa_K5237022</a></td> |
− | <td>mCherry Expression Cassette: UAS, minimal Promotor, mCherry</td> | + | <td>mCherry Expression Cassette: UAS, minimal Promotor, mCherry</td> |
− | <td>Readout system for enhancer binding. It was used to test cathepsin B-cleavable linker</td> | + | <td>Readout system for enhancer binding. It was used to test cathepsin B-cleavable linker</td> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237023" target="_blank">BBa_K5237023</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237023" target="_blank">BBa_K5237023</a></td> |
− | <td>Oct1 - 5x UAS binding casette</td> | + | <td>Oct1 - 5x UAS binding casette</td> |
− | <td>Oct1 and UAS binding cassette, that was used for the simulated enhancer hijacking assay</td> | + | <td>Oct1 and UAS binding cassette, that was used for the simulated enhancer hijacking assay</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td><a href="https://parts.igem.org/Part:BBa_K5237024" target="_blank">BBa_K5237024</a></td> | + | <td><a href="https://parts.igem.org/Part:BBa_K5237024" target="_blank">BBa_K5237024</a></td> |
− | <td>TRE-minimal promoter- firefly luciferase</td> | + | <td>TRE-minimal promoter- firefly luciferase</td> |
− | <td>Contains Firefly luciferase controlled by a minimal promoter. It was used as a luminescence readout for | + | <td>Contains Firefly luciferase controlled by a minimal promoter. It was used as a luminescence readout for |
simulated enhancer hijacking</td> | simulated enhancer hijacking</td> | ||
− | </tr> | + | </tr> |
− | </tbody> | + | </tbody> |
− | </table> | + | </table> |
− | </section> | + | </section> |
− | <section id="1"> | + | <section id="1"> |
− | <h1>1. Sequence overview</h1> | + | <h1>1. Sequence overview</h1> |
− | </section> | + | </section> |
</body> | </body> | ||
+ | |||
</html> | </html> | ||
<span class="h3bb">Sequence and Features</span> | <span class="h3bb">Sequence and Features</span> | ||
<partinfo>BBa_K5237000 SequenceAndFeatures</partinfo> | <partinfo>BBa_K5237000 SequenceAndFeatures</partinfo> | ||
<html> | <html> | ||
+ | |||
<body> | <body> | ||
− | <section id="2"> | + | <section id="2"> |
− | <h1>2. Usage and Biology</h1> | + | <h1>2. Usage and Biology</h1> |
− | <section id="2.1"> | + | <section id="2.1"> |
− | <h2>2.1 Discovery and Mechanism of CRISPR/Cas9</h2> | + | <h2>2.1 Discovery and Mechanism of CRISPR/Cas9</h2> |
− | <p> | + | |
+ | <div class="thumb tright" style="margin:0;"> | ||
+ | <div class="thumbinner" style="width:450px;"> | ||
+ | <img alt="" class="thumbimage" | ||
+ | src="https://static.igem.wiki/teams/5237/wetlab-results/cas-staple-svg/background-cas9-cas12a-principle.svg" | ||
+ | style="width:99%;" /> | ||
+ | <div class="thumbcaption"> | ||
+ | <i> | ||
+ | <b>Figure 2: The CRISPR/Cas system (adapted from Pacesa <i>et al.</i> (2024))</b> | ||
+ | A and B, schematic structure of Cas9 and Cas12a with their sgRNA/crRNA, sitting on a DNA strand with the | ||
+ | PAM. | ||
+ | The spacer sequence forms base pairings with the dsDNA. In case of Cas9 the | ||
+ | spacer is located at the 5' prime end, for Cas12a at the 3' end of the gRNA. The scaffold of the gRNA | ||
+ | forms a specific | ||
+ | secondary structure enabling it to bind to the Cas protein. The cut sites by the cleaving domains, RuvC | ||
+ | and HNH, are | ||
+ | symbolized by the scissors | ||
+ | </i> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | <p> | ||
In 2012, Jinek <i>et al.</i> discovered the use of the Clustered Regularly Interspaced Short Palindromic Repeats | In 2012, Jinek <i>et al.</i> discovered the use of the Clustered Regularly Interspaced Short Palindromic Repeats | ||
(CRISPR)/Cas system to induce double-strand breaks in DNA. Since then, the system has been well established as a | (CRISPR)/Cas system to induce double-strand breaks in DNA. Since then, the system has been well established as a | ||
− | tool for genome editing. The CRISPR/Cas system, which originates from the bacterial immune system, is constituted | + | tool for genome editing. The CRISPR/Cas system, which originates from the bacterial immune system, is |
− | by a ribonucleoprotein complex. For class 1 CRISPR systems, the RNA is complexed by multiple Cas proteins, whereas | + | constituted |
− | class 2 systems consist of a singular protein and RNA. The class 2 type II system describes all ribonucleoprotein | + | by a ribonucleoprotein complex. For class 1 CRISPR systems, the RNA is complexed by multiple Cas proteins, |
− | complexes with Cas9 (Pacesa <i>et al.</i>, 2024). They include a CRISPR RNA (crRNA), which specifies the target with a 20 | + | whereas |
− | nucleotide (nt) spacer sequence, and a transactivating CRISPR RNA (tracrRNA), which induces the processing by the | + | class 2 systems consist of a singular protein and RNA. The class 2 type II system describes all |
+ | ribonucleoprotein | ||
+ | complexes with Cas9 (Pacesa <i>et al.</i>, 2024). They include a CRISPR RNA (crRNA), which specifies the target | ||
+ | with a 20 | ||
+ | nucleotide (nt) spacer sequence, and a transactivating CRISPR RNA (tracrRNA), which induces the processing by | ||
+ | the | ||
Cas protein (Jinek <i>et al.</i>, 2012) (Fig. 2 A). Furthermore, a specific three | Cas protein (Jinek <i>et al.</i>, 2012) (Fig. 2 A). Furthermore, a specific three | ||
nucleotide sequence (NGG) on the 3' end in the targeted DNA is needed for binding and cleavage. This is referred | nucleotide sequence (NGG) on the 3' end in the targeted DNA is needed for binding and cleavage. This is referred | ||
− | to as the protospacer adjacent motif (PAM) (Sternberg <i>et al.</i>, 2014). The most commonly used Cas9 protein is SpCas9 | + | to as the protospacer adjacent motif (PAM) (Sternberg <i>et al.</i>, 2014). The most commonly used Cas9 protein |
+ | is SpCas9 | ||
or SpyCas9, which originates from Streptococcus pyogenes (Pacesa <i>et al.</i>, 2024). | or SpyCas9, which originates from Streptococcus pyogenes (Pacesa <i>et al.</i>, 2024). | ||
</p> | </p> | ||
− | + | <p> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | <p> | + | |
A significant enhancement of this system was the introduction of single guide RNA (sgRNA)s, which combine the | A significant enhancement of this system was the introduction of single guide RNA (sgRNA)s, which combine the | ||
functions of a tracrRNA and crRNA (Mali <i>et al.</i>, 2013). | functions of a tracrRNA and crRNA (Mali <i>et al.</i>, 2013). | ||
− | Moreover, Cong (2013) established precise targeting of human endogenous loci by designing the 20 nt spacer sequence accordingly. | + | Moreover, Cong (2013) established precise targeting of human endogenous loci by designing the 20 nt spacer |
+ | sequence accordingly. | ||
</p> | </p> | ||
− | </section> | + | </section> |
− | <section id="2.2"> | + | <section id="2.2"> |
− | <h2>2.2 Differences between Cas9 and Cas12a</h2> | + | <h2>2.2 Differences between Cas9 and Cas12a</h2> |
− | <p> | + | <p> |
− | Over the following years, further CRISPR/Cas systems have been discovered, including the Cpf1 system, which has been | + | Over the following years, further CRISPR/Cas systems have been discovered, including the Cpf1 system, which has |
+ | been | ||
classified as Cas12a since then (Zetsche <i>et al.</i>, 2015). | classified as Cas12a since then (Zetsche <i>et al.</i>, 2015). | ||
Cas12a forms a class 2 type V system with its RNA, that in comparison to the type II | Cas12a forms a class 2 type V system with its RNA, that in comparison to the type II | ||
systems, only requires a crRNA for targeting and activation. Cas12a is capable of processing the precursor crRNA | systems, only requires a crRNA for targeting and activation. Cas12a is capable of processing the precursor crRNA | ||
into crRNA independently, whereas Cas9 requires the RNase III enzyme and tracrRNA for this process (Paul and | into crRNA independently, whereas Cas9 requires the RNase III enzyme and tracrRNA for this process (Paul and | ||
− | Montoya, 2020). This crRNA is often also referred to as a guide RNA (gRNA). However, the stem loop that is formed | + | Montoya, 2020). This crRNA is often also referred to as a guide RNA (gRNA). However, the stem loop that is |
− | when binding the Cas protein is structurally distinct to the Cas9 gRNA and positioned on the 5' side of the crRNA | + | formed |
+ | when binding the Cas protein is structurally distinct to the Cas9 gRNA and positioned on the 5' side of the | ||
+ | crRNA | ||
(Fig. 2 B). Similarly, the PAM (TTTV) is also on the 5' side (Pacesa <i>et al.</i>, | (Fig. 2 B). Similarly, the PAM (TTTV) is also on the 5' side (Pacesa <i>et al.</i>, | ||
2024). Cas9 possesses RuvC and HNH domains that are catalytically active, each of which cleaves one of the DNA | 2024). Cas9 possesses RuvC and HNH domains that are catalytically active, each of which cleaves one of the DNA | ||
− | strands at the same site, resulting in the formation of blunt end cuts (Nishimasu <i>et al.</i>, 2014). Cas12a possesses | + | strands at the same site, resulting in the formation of blunt end cuts (Nishimasu <i>et al.</i>, 2014). Cas12a |
− | one RuvC-like domain that creates staggered cuts with overhangs that are about 5nt long (Paul and Montoya, 2020). | + | possesses |
+ | one RuvC-like domain that creates staggered cuts with overhangs that are about 5nt long (Paul and Montoya, | ||
+ | 2020). | ||
</p> | </p> | ||
− | </section> | + | </section> |
− | <section id="2.3"> | + | <section id="2.3"> |
− | <h2>2.3 Dead Cas Proteins and their Application</h2> | + | <h2>2.3 Dead Cas Proteins and their Application</h2> |
− | <p> | + | <p> |
Specific mutations of these domains result in catalytic inactivity and therefore allow for the creation of | Specific mutations of these domains result in catalytic inactivity and therefore allow for the creation of | ||
nickases that only cut one of the DNA strands, or completely inactive Cas proteins (Koonin <i>et al.</i>, 2023) | nickases that only cut one of the DNA strands, or completely inactive Cas proteins (Koonin <i>et al.</i>, 2023) | ||
− | (Kleinstiver <i>et al.</i>, 2019). These are referred to as dead Cas proteins or dCas9 and dCas12a. These Cas proteins | + | (Kleinstiver <i>et al.</i>, 2019). These are referred to as dead Cas proteins or dCas9 and dCas12a. These Cas |
− | can be used to activate (CRISPRa) or inhibit (CRISPRi) the expression of genes by fusing them to effector domains | + | proteins |
+ | can be used to activate (CRISPRa) or inhibit (CRISPRi) the expression of genes by fusing them to effector | ||
+ | domains | ||
and targeting the respective gene with the spacer sequence (Kampmann, 2017). A common approach for CRISPRa | and targeting the respective gene with the spacer sequence (Kampmann, 2017). A common approach for CRISPRa | ||
− | involves fusing Cas9 with the transcriptional activator VP64 (Kampmann, 2017). | + | involves fusing Cas9 with the transcriptional activator VP64 (Kampmann, 2017). |
</p> | </p> | ||
− | </section> | + | </section> |
− | <section id="2.4"> | + | <section id="2.4"> |
− | <h2>2.4 fgRNA and CHyMErA System</h2> | + | <h2>2.4 fgRNA and CHyMErA System</h2> |
− | <p> | + | <div class="thumb tright" style="margin:0;"> |
− | Kweon <i>et al.</i> (2017) further expanded the ways in which the CRISPR/Cas system could be used by introducing the concept of fusion guide RNA | + | <div class="thumbinner" style="width:400px;"> |
+ | <img alt="" class="thumbimage" | ||
+ | src="https://static.igem.wiki/teams/5237/wetlab-results/cas-staple-svg/background-crispr-cas-system-fgrna-past.svg" | ||
+ | style="width:99%;" /> | ||
+ | <div class="thumbcaption"> | ||
+ | <i> | ||
+ | <b>Figure 3: Applications of the Fusion Guide RNA (adapted from Kweon <i>et al.</i> (2017)).</b> | ||
+ | Fusion Guide RNAs can be used for multiplex genome editing by guidingactive Cas12a and Cas9 to two | ||
+ | distinct loci. Similarly, fgRNAs allow for CRISPRa, by guiding the Cas9-VP64 transcriptional activator | ||
+ | towards a | ||
+ | target locus. | ||
+ | </i> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <p> | ||
+ | Kweon <i>et al.</i> (2017) further expanded the ways in which the CRISPR/Cas system could be used by introducing | ||
+ | the concept of fusion guide RNA | ||
(fgRNA)s. By fusing the 3' end of a Cas12a gRNA to the 5' end of a Cas9 gRNA, the newly created fgRNA could be | (fgRNA)s. By fusing the 3' end of a Cas12a gRNA to the 5' end of a Cas9 gRNA, the newly created fgRNA could be | ||
used by both proteins independently for either multiplex genome editing or transcriptional regulation and genome | used by both proteins independently for either multiplex genome editing or transcriptional regulation and genome | ||
Line 387: | Line 468: | ||
possible using the Cas Hybrid for Multiplexed Editing and screening Applications (CHyMErA) system | possible using the Cas Hybrid for Multiplexed Editing and screening Applications (CHyMErA) system | ||
(Gonatopoulos-Pournatzis <i>et al.</i>, 2020). | (Gonatopoulos-Pournatzis <i>et al.</i>, 2020). | ||
− | + | In this instance, the gRNAs of Cas12a and Cas9 are connected in the | |
− | opposite direction (3' Cas9 gRNA to 5' Cas12a gRNA), allowing for Cas12a to process the RNA into individual units | + | opposite direction (3' Cas9 gRNA to 5' Cas12a gRNA), allowing for Cas12a to process the RNA into individual |
+ | units | ||
(Fig. 3). Amongst other things, this allows for the analysis | (Fig. 3). Amongst other things, this allows for the analysis | ||
− | of the interaction between different genes by targeting them simultaneously with the two distinct spacers (Aregger | + | of the interaction between different genes by targeting them simultaneously with the two distinct spacers |
+ | (Aregger | ||
<i>et al.</i>, 2021) (Fig. 3). | <i>et al.</i>, 2021) (Fig. 3). | ||
</p> | </p> | ||
− | < | + | |
− | < | + | </section> |
− | < | + | </section > |
− | + | <section style="clear:both;" id="3"> | |
− | + | <h1>3. Assembly and part evolution</h1> | |
− | + | <p> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | <h1>3. Assembly and part evolution</h1> | + | |
− | <p> | + | |
Building on insights of our fusion Cas engineering cycle and findings from Kweon (2017), fgRNAs were designed by | Building on insights of our fusion Cas engineering cycle and findings from Kweon (2017), fgRNAs were designed by | ||
combining the sgRNA from SpCas9 with the crRNA from MbCas12a, specifically the 3'-end of the MbCas12a gRNA was | combining the sgRNA from SpCas9 with the crRNA from MbCas12a, specifically the 3'-end of the MbCas12a gRNA was | ||
Line 418: | Line 490: | ||
MbCas12a scaffold, a bacterial promoter driving <b>ccdB</b> expression, and the SpCas9 scaffold. Successful spacer | MbCas12a scaffold, a bacterial promoter driving <b>ccdB</b> expression, and the SpCas9 scaffold. Successful spacer | ||
integration leads to the removal of the <b>ccdB</b> gene, allowing bacterial growth to be used as an indicator for | integration leads to the removal of the <b>ccdB</b> gene, allowing bacterial growth to be used as an indicator for | ||
− | cloning success.<br/> | + | cloning success.<br /> |
An existing vector containing the U6 promoter and the MbCas12a scaffold was selected as the basis | An existing vector containing the U6 promoter and the MbCas12a scaffold was selected as the basis | ||
for entry vector cloning. The vector and a ccdB-SpCas9 scaffold construct were PCR amplified and fitting overhangs | for entry vector cloning. The vector and a ccdB-SpCas9 scaffold construct were PCR amplified and fitting overhangs | ||
for SapI were introduced. Golden Gate assembly (GGA) with Esp3I was used to create the final plasmid. The | for SapI were introduced. Golden Gate assembly (GGA) with Esp3I was used to create the final plasmid. The | ||
− | transformation was carried out in the ccdB-resistant XL1 Blue<i>E. Coli </i> strain. | + | transformation was carried out in the ccdB-resistant XL1 Blue<i>E. Coli </i> strain. |
</p> | </p> | ||
− | <div class="thumb"> | + | <div class="thumb"> |
− | <div class="thumbinner" style="width:80%;"> | + | <div class="thumbinner" style="width:80%;"> |
− | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/entry-vector.svg" style="width:99%;"/> | + | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/entry-vector.svg" |
− | <div class="thumbcaption"> | + | style="width:99%;" /> |
− | <i> | + | <div class="thumbcaption"> |
− | <b>Figure 4: Construction process of fgRNAs using the entry vector.</b> The ccdB gene can be cut out using SapI in the Golden Gate | + | <i> |
− | + | <b>Figure 4: Construction process of fgRNAs using the entry vector.</b> The ccdB gene can be cut out using | |
− | + | SapI in the Golden Gate | |
+ | assembly. By inserting oligonucleotides with the desired spacer sequences and matching overhangs, the | ||
+ | complete fgRNA | ||
+ | can be expressed. Due to the cytotoxic nature of ccdB, only cells with the oligonucleotides as inserts | ||
+ | survive. | ||
</i> | </i> | ||
− | </div> | + | </div> |
− | </div> | + | </div> |
− | <p> | + | <p> |
− | + | The first goal after assembly was to prove the editing activity of both proteins using fgRNA. The genes | |
− | + | VEGFA and FANCF were selected as targets for Cas12a and Cas9, each target was tested with each Cas protein. | |
− | + | Editing efficiency will be analyzed with the T7 Endonuclease I (T7EI) assay. Controls will include crRNAs and | |
− | + | sgRNAs as positive controls, and non-targeting guides as negative controls. Desired spacer sequences can be | |
− | + | ordered as oligos, annealed, and cloned in via GGA utilizing SapI. | |
− | + | </p> | |
− | <table style="width:40%; margin-top:20px; margin-bottom:20px;"> | + | <table style="width:40%; margin-top:20px; margin-bottom:20px;"> |
− | <thead> | + | <thead> |
− | <td align="left" colspan="2"> | + | <td align="left" colspan="2"> |
− | <b>Table 1:</b> A list of all the different spacers we cloned and tested within the fgRNA | + | <b>Table 1:</b> A list of all the different spacers we cloned and tested within the fgRNA |
− | + | </td> | |
− | </thead> | + | </thead> |
− | <tbody> | + | <tbody> |
− | <tr> | + | <tr> |
− | <td>VEGFA</td> | + | <td>VEGFA</td> |
− | <td>ctaggaatattgaagggggc</td> | + | <td>ctaggaatattgaagggggc</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td>FANCF</td> | + | <td>FANCF</td> |
− | <td>ggcggggtccagttccggga</td> | + | <td>ggcggggtccagttccggga</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td>CCR5</td> | + | <td>CCR5</td> |
− | <td>tgacatcaattattatacat</td> | + | <td>tgacatcaattattatacat</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td>TetO (<a href="https://parts.igem.org/Part:BBa_K5237019" target="_blank">BBa_K5237019</a>)</td> | + | <td>TetO (<a href="https://parts.igem.org/Part:BBa_K5237019" target="_blank">BBa_K5237019</a>)</td> |
− | <td>tctctatcactgatagggag</td> | + | <td>tctctatcactgatagggag</td> |
− | </tr> | + | </tr> |
− | <tr> | + | <tr> |
− | <td>Oct1-B (<a href="https://parts.igem.org/Part:BBa_K5237018" target="_blank">BBa_K5237018</a>)</td> | + | <td>Oct1-B (<a href="https://parts.igem.org/Part:BBa_K5237018" target="_blank">BBa_K5237018</a>)</td> |
− | <td>atgcaaatactgcactagtg</td> | + | <td>atgcaaatactgcactagtg</td> |
− | </tr> | + | </tr> |
− | </tbody> | + | </tbody> |
− | </table> | + | </table> |
− | <p> | + | <p> |
− | + | We constructed a second entry vector incorporating an AsCas12a scaffold (5' taatttctactcttgtagat 3') instead of | |
− | + | MbCas12a. | |
− | + | The sequence of the AsCas12a scaffold, was the only modification in the composite part. This vector was tested | |
− | + | on the | |
− | </div></section> | + | loci VEGFA and FANCF to assess its functionality. |
− | <section id="4"> | + | </p> |
− | <h1>4. Results</h1> | + | </div> |
− | <section id="4.1"><h2>4.1 Editing endogenous loci with fgRNAs</h2> | + | </section> |
− | <p> | + | <section id="4"> |
− | + | <h1>4. Results</h1> | |
− | + | <section id="4.1"> | |
− | + | <h2>4.1 Editing endogenous loci with fgRNAs</h2> | |
+ | <p> | ||
+ | To prove that our fusion gRNAs still result in active ribonucleoproteins, a series of different fgRNAs were | ||
+ | created, each carrying spacers specific to the VEGFA and FANCF genes.HEK293-T cells were transfected with the | ||
+ | Cas | ||
+ | protein and gRNA constructs. The editing rate was tested 72h after transfection via a T7 endonuclease I | ||
+ | assay.<br /> | ||
− | + | AsCas12a and SpCas9 were used. The AsCas12a spacer targets VEGFA, while the SpCas9 spacer targets FANCF. The | |
− | + | samples included standard single gRNAs with the corresponding Cas protein, the fgRNA with only one of the two | |
− | + | Cas | |
− | + | proteins and the fgRNA with both Cas proteins simultaneously (Fig. 5). The sgRNAs allowed for | |
− | + | the highest editing rates for both genes (45% for VEGFA and 15% for FANCF), while the editing rates for FANCF | |
− | + | were | |
− | + | consistently lower in all experiments. Importantly, targeting FANCF with fgRNAs resulted in noticeable editing | |
− | + | of | |
− | + | about 10%, with just the SpCas9 and both Cas proteins in the sample. For VEGFA, the AsCas12a only sample | |
− | + | resulted | |
− | <div class="thumb"> | + | in approximately 20% editing rate in combination with the fgRNA, while adding both Cas proteins led to |
− | <div class="thumbinner" style="width:60%;"> | + | approximately 40%. These initial results confirmed our engineering approach proving efficient genome editing |
− | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-ascas-2.svg" style="width:99%;"/> | + | with |
− | <div class="thumbcaption"> | + | fgRNAs. |
− | <i> | + | </p> |
− | <b>Figure 5: fgRNAs Enable Efficient Editing of Endogenous Loci.</b> | + | <div class="thumb"> |
− | + | <div class="thumbinner" style="width:60%;"> | |
− | + | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-ascas-2.svg" | |
− | + | style="width:99%;" /> | |
− | + | <div class="thumbcaption"> | |
− | + | <i> | |
− | </div> | + | <b>Figure 5: fgRNAs Enable Efficient Editing of Endogenous Loci.</b> |
− | </div> | + | The editing rates were determined 72h after transfection via T7EI assay. Editing % was determined by |
− | </div> | + | measuring band |
− | </section> | + | intensities; Editing % = 100 x (1 - (1- cleaved band/uncleaved band))<sup>1/2</sup>. The schematic at the |
− | <section id="4.2"><h2>4.2 Fusion Guide RNAs Allow for Editing Rates With Variant Cas Orthologs</h2> | + | top shows the |
− | <p> | + | composition of the fgRNA. Below each spacer is the targeted gene. The symbols below indicate which parts |
+ | are included in | ||
+ | each sample. | ||
+ | </i> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </section> | ||
+ | <section id="4.2"> | ||
+ | <h2>4.2 Fusion Guide RNAs Allow for Editing Rates With Variant Cas Orthologs</h2> | ||
+ | <p> | ||
To further evaluate the capabilities of the fgRNAs, we tested them in combination | To further evaluate the capabilities of the fgRNAs, we tested them in combination | ||
with different Cas12a orthologs. After some initial testing, we decided on using MbCas12a together with SpCas9, | with different Cas12a orthologs. After some initial testing, we decided on using MbCas12a together with SpCas9, | ||
− | because we found AsCas12a to be less active in a dual luciferase assay when co-transfected with SpCas9 compared to | + | because we found AsCas12a to be less active in a dual luciferase assay when co-transfected with SpCas9 compared |
+ | to | ||
MbCas12a (Fig. 6). Between these two co-transfections the | MbCas12a (Fig. 6). Between these two co-transfections the | ||
SpCas9 editing has not been significantly different. | SpCas9 editing has not been significantly different. | ||
</p> | </p> | ||
− | <div class="thumb"> | + | <div class="thumb"> |
− | <div class="thumbinner" style="width:60%;"> | + | <div class="thumbinner" style="width:60%;"> |
− | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-ascas-2.svg" style="width:99%;"/> | + | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-ascas-2.svg" |
− | <div class="thumbcaption"> | + | style="width:99%;" /> |
− | <i> | + | <div class="thumbcaption"> |
− | <b>Figure 6: Comparison of AsCas12a and MbCas12a with a dual luciferae assay.</b> | + | <i> |
− | Firefly luminescence intensity measured 48 h after transfection. Normalized against renilla luminescence. On the x-axis | + | <b>Figure 6: Comparison of AsCas12a and MbCas12a with a dual luciferae assay.</b> |
+ | Firefly luminescence intensity measured 48 h after transfection. Normalized against renilla luminescence. | ||
+ | On the x-axis | ||
the samples Cas9 + AsCas12a , Cas9 + MbCas12a, AsCas12a and MbCas12a are depicted. | the samples Cas9 + AsCas12a , Cas9 + MbCas12a, AsCas12a and MbCas12a are depicted. | ||
Data is depicted as the mean +/- SD (n=3). | Data is depicted as the mean +/- SD (n=3). | ||
− | Statistical analysis was performed using 1way ANOVA with Tukey's multiple comparisons test. For better clarity, only | + | Statistical analysis was performed using 1way ANOVA with Tukey's multiple comparisons test. For better |
− | significant differences within a group between the same Cas proteins are shown.*p<0.05, **p<0.01, ***p<0.001, | + | clarity, only |
− | + | significant differences within a group between the same Cas proteins are shown.*p<0.05, **p<0.01, | |
+ | ***p<0.001, | ||
+ | ****p<0.0001 | ||
</i> | </i> | ||
− | </div> | + | </div> |
− | </div> | + | </div> |
− | </div> | + | </div> |
− | <p> | + | <p> |
Additionally, to test if the differences in editing rates from the preliminary assay resulted from the targeted | Additionally, to test if the differences in editing rates from the preliminary assay resulted from the targeted | ||
loci or the different Cas orthologs, the spacers were tested in both arrangements. Once with Cas12a targeting | loci or the different Cas orthologs, the spacers were tested in both arrangements. Once with Cas12a targeting | ||
− | FANCF and SpCas9 targeting VEGFA and once vice versa. To better assess the impact that the utilization of a fgRNA | + | FANCF and SpCas9 targeting VEGFA and once vice versa. To better assess the impact that the utilization of a |
− | has on the editing rates, the sgRNAs were tested separately and in one sample.<br/> | + | fgRNA |
+ | has on the editing rates, the sgRNAs were tested separately and in one sample.<br /> | ||
Having the sgRNA with single Cas | Having the sgRNA with single Cas | ||
− | proteins in the same sample resulted in no clear difference in the editing rates (Fig. 7). The fusion of the gRNAs resulted in a lower editing rate overall. While the editing for VEGFA | + | proteins in the same sample resulted in no clear difference in the editing rates (Fig. 7). The fusion of the |
− | stayed at about 20% in all cases, the editing for FANCF dropped significantly. When targeting the same gene under | + | gRNAs resulted in a lower editing rate overall. While the editing for VEGFA |
+ | stayed at about 20% in all cases, the editing for FANCF dropped significantly. When targeting the same gene | ||
+ | under | ||
the same conditions, the editing rates for MbCas12a were overall lower than the ones from SpCas9. | the same conditions, the editing rates for MbCas12a were overall lower than the ones from SpCas9. | ||
</p> | </p> | ||
− | <div class="thumb"> | + | <div class="thumb"> |
− | <div class="thumbinner" style="width:90%;"> | + | <div class="thumbinner" style="width:90%;"> |
− | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-mbcas-2.svg" style="width:99%;"/> | + | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-mbcas-2.svg" |
− | <div class="thumbcaption"> | + | style="width:99%;" /> |
− | <i> | + | <div class="thumbcaption"> |
− | <b>Figure 7: Fusion gRNA Editing Rates In Combination with MbCas12a.</b> | + | <i> |
+ | <b>Figure 7: Fusion gRNA Editing Rates In Combination with MbCas12a.</b> | ||
In <b>A</b> and <b>B</b> the editing rates were determined 72h after transfection via T7EI | In <b>A</b> and <b>B</b> the editing rates were determined 72h after transfection via T7EI | ||
− | assay. Editing % was determined by measuring band intensities; Editing % = 100 x (1 - (1- cleaved band/uncleaved band) | + | assay. Editing % was determined by measuring band intensities; Editing % = 100 x (1 - (1- cleaved |
− | <sup>1/2</sup>). The schematic at the top shows the composition of the fgRNA. Below each spacer is the targeted gene. The | + | band/uncleaved band) |
+ | <sup>1/2</sup>). The schematic at the top shows the composition of the fgRNA. Below each spacer is the | ||
+ | targeted gene. The | ||
symbols below indicate which parts are included in each sample. <b>A</b> and <b>B</b> | symbols below indicate which parts are included in each sample. <b>A</b> and <b>B</b> | ||
display both orientations of the two spacers for VEGFA and FANCF. | display both orientations of the two spacers for VEGFA and FANCF. | ||
</i> | </i> | ||
− | </div> | + | </div> |
− | </div> | + | </div> |
− | </div></section> | + | </div> |
− | <section id="4.3"><h2>4.3 The Inclusion of a Linker Does Not Lower Editing Rates</h2> | + | </section> |
− | <p> | + | <section id="4.3"> |
+ | <h2>4.3 The Inclusion of a Linker Does Not Lower Editing Rates</h2> | ||
+ | <p> | ||
To further assess the effect of the genomic locus on the editing rate, we included CCR5 as an additional | To further assess the effect of the genomic locus on the editing rate, we included CCR5 as an additional | ||
gene target. For this assay, a fgRNA with a 20 nt long linker was included between the two spacers. The editing | gene target. For this assay, a fgRNA with a 20 nt long linker was included between the two spacers. The editing | ||
rate for VEGFA was again relatively consistent throughout the samples (Fig. 8). For CCR5, the | rate for VEGFA was again relatively consistent throughout the samples (Fig. 8). For CCR5, the | ||
− | editing rate with sgRNAs was approximately the same at about 30%. However, it dropped below 10% for the fgRNA. The | + | editing rate with sgRNAs was approximately the same at about 30%. However, it dropped below 10% for the fgRNA. |
− | addition of the 20 nt linker had no effect on the editing rates compared to no linker. | + | The |
+ | addition of the 20 nt linker had no effect on the editing rates compared to no linker. | ||
</p> | </p> | ||
− | <div class="thumb"> | + | <div class="thumb"> |
− | <div class="thumbinner" style="width:60%;"> | + | <div class="thumbinner" style="width:60%;"> |
− | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-ccr5-2.svg" style="width:99%;"/> | + | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-ccr5-2.svg" |
− | <div class="thumbcaption"> | + | style="width:99%;" /> |
− | <i> | + | <div class="thumbcaption"> |
− | <b>Figure 8: Fusion gRNA Editing Rates for Multiplexing CCR5 and VEGFA</b> | + | <i> |
− | The editing rates were determined 72h after transfection via T7EI assay. Editing % was determined by measuring band | + | <b>Figure 8: Fusion gRNA Editing Rates for Multiplexing CCR5 and VEGFA</b> |
− | intensities; Editing % = 100 x (1 - (1- cleaved band/uncleaved band))<sup>1/2</sup>. The schematic at the top shows the | + | The editing rates were determined 72h after transfection via T7EI assay. Editing % was determined by |
− | composition of the fgRNA. Below each spacer is the targeted gene. The symbols below indicate which parts are included in | + | measuring band |
+ | intensities; Editing % = 100 x (1 - (1- cleaved band/uncleaved band))<sup>1/2</sup>. The schematic at the | ||
+ | top shows the | ||
+ | composition of the fgRNA. Below each spacer is the targeted gene. The symbols below indicate which parts | ||
+ | are included in | ||
each sample. Cas12a targets VEGFA and Cas9 targets CCR5. | each sample. Cas12a targets VEGFA and Cas9 targets CCR5. | ||
</i> | </i> | ||
− | </div> | + | </div> |
− | </div> | + | </div> |
− | </div> | + | </div> |
− | </section> | + | </section> |
− | <section id="4.4"><h2>4.4 fgRNAs can be used for CRISPRa</h2> | + | <section id="4.4"> |
− | <p> | + | <h2>4.4 fgRNAs can be used for CRISPRa</h2> |
− | To establish the foundation for their use as protein scaffolds, we identified the next step as demonstrating the use | + | <p> |
+ | To establish the foundation for their use as protein scaffolds, we identified the next step as demonstrating the | ||
+ | use | ||
of fgRNAs for CRISPR activation. For this, we intend to recruit the transcriptional activator VP64 to a firefly | of fgRNAs for CRISPR activation. For this, we intend to recruit the transcriptional activator VP64 to a firefly | ||
luciferase gene to induce expression. The VP64 protein is attached to the catalytically inactive Cas9 protein, | luciferase gene to induce expression. The VP64 protein is attached to the catalytically inactive Cas9 protein, | ||
Line 590: | Line 702: | ||
front of the luciferase gene in multiple repeats. The firefly luciferase activity was then quantified as photon | front of the luciferase gene in multiple repeats. The firefly luciferase activity was then quantified as photon | ||
counts and normalized against Renilla luciferase, which is expressed on a separate plasmid under an ubiquitous | counts and normalized against Renilla luciferase, which is expressed on a separate plasmid under an ubiquitous | ||
− | promoter. In two biological replicates we saw similar Relative luciferase activity with fgRNA as a guide compared | + | promoter. In two biological replicates we saw similar Relative luciferase activity with fgRNA as a guide |
− | to a sgRNA (Fig. 9). | + | compared |
+ | to a sgRNA (Fig. 9). | ||
</p> | </p> | ||
− | <div class="thumb"> | + | <div class="thumb"> |
− | <div class="thumbinner" style="width:40%;"> | + | <div class="thumbinner" style="width:40%;"> |
− | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-crispra-2.svg" style="width:99%;"/> | + | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-crispra-2.svg" |
− | <div class="thumbcaption"> | + | style="width:99%;" /> |
− | <i> | + | <div class="thumbcaption"> |
− | <b>Figure 9: CRISPRa Induced Luciferase Expression for sgRNAs and fgRNAs.</b> | + | <i> |
− | Firefly luciferase activity was measured 48h after transfection. Normalized against ubiquitously expressed Renilla | + | <b>Figure 9: CRISPRa Induced Luciferase Expression for sgRNAs and fgRNAs.</b> |
− | luciferase. The tetO repeats were targeted by Cas9-VP64, once with a sgRNA and once with a fgRNA that had a | + | Firefly luciferase activity was measured 48h after transfection. Normalized against ubiquitously expressed |
− | non-targeting sequence for the Cas12a spacer. The schematic at the top shows the composition of the fgRNA. Below each | + | Renilla |
+ | luciferase. The tetO repeats were targeted by Cas9-VP64, once with a sgRNA and once with a fgRNA that had | ||
+ | a | ||
+ | non-targeting sequence for the Cas12a spacer. The schematic at the top shows the composition of the fgRNA. | ||
+ | Below each | ||
spacer is the targeted gene. The symbols below indicate which parts are included in each sample. | spacer is the targeted gene. The symbols below indicate which parts are included in each sample. | ||
</i> | </i> | ||
− | </div> | + | </div> |
− | </div> | + | </div> |
− | </div> | + | </div> |
− | </section> | + | </section> |
− | <section id="4.5"> <h2>4.5 Stapling Two DNA Strands Together Using fgRNAs</h2> | + | <section id="4.5"> |
− | <p> | + | <h2>4.5 Stapling Two DNA Strands Together Using fgRNAs</h2> |
+ | <p> | ||
After showing the general capability of the fgRNA | After showing the general capability of the fgRNA | ||
to work for editing and for CRISPR activation, the next step was to use it to staple two DNA loci together, and | to work for editing and for CRISPR activation, the next step was to use it to staple two DNA loci together, and | ||
thereby induce proximity between two separate functional elements. For this, an enhancer plasmid and a reporter | thereby induce proximity between two separate functional elements. For this, an enhancer plasmid and a reporter | ||
− | plasmid was used. The reporter plasmid has firefly luciferase behind several repeats of a Cas9 targeted sequence. | + | plasmid was used. The reporter plasmid has firefly luciferase behind several repeats of a Cas9 targeted |
− | The enhancer plasmid has a Gal4 binding site behind several repeats of a Cas12a targeted sequence. By introducing | + | sequence. |
− | a fgRNA staple and a Gal4-VP64, expression of the luciferase is induced (Fig. 10, Panel A). | + | The enhancer plasmid has a Gal4 binding site behind several repeats of a Cas12a targeted sequence. By |
− | Different linker lengths were tested. Cells were again normalized against ubiquitous renilla expression.<br/> | + | introducing |
− | Using no linker between the two spacers showed similar relative luciferase activity to the baseline control | + | a fgRNA staple and a Gal4-VP64, expression of the luciferase is induced (Fig. 10, Panel A). |
− | (Fig. 10, Panel B). An extension of the linker from 20 nt up to 40 nt resulted in an increasingly higher expression of the | + | Different linker lengths were tested. Cells were again normalized against ubiquitous renilla expression.<br /> |
+ | Using no linker between the two spacers showed similar relative luciferase activity to the baseline control | ||
+ | (Fig. 10, Panel B). An extension of the linker from 20 nt up to 40 nt resulted in an increasingly higher | ||
+ | expression of the | ||
reporter gene. These results suggest an extension of the linker might lead to better transactivation when | reporter gene. These results suggest an extension of the linker might lead to better transactivation when | ||
hijacking an enhancer/activator. | hijacking an enhancer/activator. | ||
+ | </p> | ||
+ | <div class="thumb"> | ||
+ | <div class="thumbinner" style="width:60%;"> | ||
+ | <img alt="" class="thumbimage" src="https://static.igem.wiki/teams/5237/wetlab-results/results-eh-2.svg" | ||
+ | style="width:99%;" /> | ||
+ | <div class="thumbcaption"> | ||
+ | <i> | ||
+ | <b>Figure 10: Applying Fusion Guide RNAs for Cas staples.</b> <b>A</b>, schematic overview of the assay. | ||
+ | An enhancer | ||
+ | plasmid and a reporter plasmid are brought into proximity by a fgRNA Cas staple complex binding both | ||
+ | plasmids. Target | ||
+ | sequences were included in multiple repeats prior to the functional elements. Firefly luciferase serves as | ||
+ | the reporter | ||
+ | gene, the enhancer is constituted by multiple Gal4 repeats that are bound by a Gal4-VP64 fusion. | ||
+ | <b>B</b>, results of using a fgRNA Cas staple for trans activation of firefly luciferase. Firefly | ||
+ | luciferase activity was measured 48h after transfection. Normalized against ubiquitously expressed Renilla | ||
+ | luciferase. | ||
+ | Statistical significance was calculated with ordinary One-way ANOVA with Dunn's method for multiple | ||
+ | comparisons (*p < | ||
+ | 0.05; **p < 0.01; ***p < 0.001; mean +/- SD). The assay included sgRNAs and fgRNAs with linker | ||
+ | lengths from 0 nt | ||
+ | to 40 nt. | ||
+ | </i> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </section> | ||
+ | </section> | ||
+ | <section id="5"> | ||
+ | <h1>5. References</h1> | ||
+ | <p>Aregger, M., Xing, K., & Gonatopoulos-Pournatzis, T. (2021). Application of CHyMErA Cas9-Cas12a combinatorial | ||
+ | genome-editing platform for genetic interaction mapping and gene fragment deletion screening. <i>Nature | ||
+ | Protocols</i>, 16, 4722-4765. <a href="https://doi.org/10.1038/s41596-021-00595-1" | ||
+ | target="_blank">https://doi.org/10.1038/s41596-021-00595-1</a></p> | ||
+ | <p>Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. | ||
+ | A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. <i>Science</i>, 339, 819-823. | ||
+ | <a href="https://doi.org/10.1126/science.1231143" target="_blank">https://doi.org/10.1126/science.1231143</a></p> | ||
+ | <p>Gonatopoulos-Pournatzis, T., Aregger, M., Brown, K. R., Farhangmehr, S., Braunschweig, U., Ward, H. N., Ha, K. C. | ||
+ | H., Weiss, A., Billmann, M., Durbic, T., Myers, C. L., Blencowe, B. J., & Moffat, J. (2020). Genetic | ||
+ | interaction mapping and exon-resolution functional genomics with a hybrid Cas9-Cas12a platform. <i>Nature | ||
+ | Biotechnology</i>, 38, 638-648. <a href="https://doi.org/10.1038/s41587-020-0437-z" | ||
+ | target="_blank">https://doi.org/10.1038/s41587-020-0437-z</a></p> | ||
+ | <p>Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable | ||
+ | dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. <i>Science</i>, 337, 816-821. <a | ||
+ | href="https://doi.org/10.1126/science.1225829" target="_blank">https://doi.org/10.1126/science.1225829</a></p> | ||
+ | <p>Kampmann, M. (2017). CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. <i>ACS | ||
+ | Chemical Biology</i>, 13, 406-416. <a href="https://doi.org/10.1021/acschembio.7b00657" | ||
+ | target="_blank">https://doi.org/10.1021/acschembio.7b00657</a></p> | ||
+ | <p>Kleinstiver, B. P., Sousa, A. A., Walton, R. T., Tak, Y. E., Hsu, J. Y., Clement, K., Welch, M. M., Horng, J. E., | ||
+ | Malagon-Lopez, J., Scarfò, I., Maus, M. V., Pinello, L., Aryee, M. J., & Joung, J. K. (2019). Engineered | ||
+ | CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base | ||
+ | editing. <i>Nature Biotechnology</i>, 37, 276-282. <a href="https://doi.org/10.1038/s41587-018-0011-0" | ||
+ | target="_blank">https://doi.org/10.1038/s41587-018-0011-0</a></p> | ||
+ | <p>Koonin, E. V., Gootenberg, J. S., & Abudayyeh, O. O. (2023). Discovery of diverse CRISPR-Cas systems and | ||
+ | expansion of the genome engineering toolbox. <i>Biochemistry</i>, 62, 3465-3487. <a | ||
+ | href="https://doi.org/10.1021/acs.biochem.3c00159" | ||
+ | target="_blank">https://doi.org/10.1021/acs.biochem.3c00159</a></p> | ||
+ | <p>Kweon, J., Jang, A.-H., Kim, D.-e., Yang, J. W., Yoon, M., Rim Shin, H., Kim, J.-S., & Kim, Y. (2017). Fusion | ||
+ | guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1. <i>Nature Communications</i>, 8. <a | ||
+ | href="https://doi.org/10.1038/s41467-017-01650-w" target="_blank">https://doi.org/10.1038/s41467-017-01650-w</a> | ||
</p> | </p> | ||
− | + | <p>Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. | |
− | + | (2013). RNA-guided human genome engineering via Cas9. <i>Science</i>, 339, 823-826. <a | |
− | + | href="https://doi.org/10.1126/science.1232033" target="_blank">https://doi.org/10.1126/science.1232033</a></p> | |
− | + | <p>Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & | |
− | + | Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. <i>Cell</i>, 156, 935-949. | |
− | + | <a href="https://doi.org/10.1016/j.cell.2014.02.001" | |
− | + | target="_blank">https://doi.org/10.1016/j.cell.2014.02.001</a></p> | |
− | + | <p>Pacesa, M., Pelea, O., & Jinek, M. (2024). Past, present, and future of CRISPR genome editing technologies. | |
− | + | <i>Cell</i>, 187, 1076-1100. <a href="https://doi.org/10.1016/j.cell.2024.01.042" | |
− | + | target="_blank">https://doi.org/10.1016/j.cell.2024.01.042</a></p> | |
− | + | <p>Paul, B., & Montoya, G. (2020). CRISPR-Cas12a: Functional overview and applications. <i>Biomedical | |
− | + | Journal</i>, 43, 8-17. <a href="https://doi.org/10.1016/j.bj.2019.10.005" | |
− | + | target="_blank">https://doi.org/10.1016/j.bj.2019.10.005</a></p> | |
− | + | <p>Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014). DNA interrogation by the | |
− | + | CRISPR RNA-guided endonuclease Cas9. <i>Nature</i>, 507, 62-67. <a href="https://doi.org/10.1038/nature13011" | |
− | + | target="_blank">https://doi.org/10.1038/nature13011</a></p> | |
− | + | <p>Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. | |
− | + | E., Joung, J., van der Oost, J., Regev, A., Koonin, E. V., & Zhang, F. (2015). Cpf1 is a single RNA-guided | |
− | + | endonuclease of a class 2 CRISPR-Cas system. <i>Cell</i>, 163, 759-771. <a | |
− | + | href="https://doi.org/10.1016/j.cell.2015.09.038" target="_blank">https://doi.org/10.1016/j.cell.2015.09.038</a> | |
− | + | </p> | |
− | + | </section> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | <p>Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. <i>Science</i>, 339, 823-826. <a href="https://doi.org/10.1126/science.1232033" target="_blank">https://doi.org/10.1126/science.1232033</a></p> | + | |
− | <p>Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. <i>Cell</i>, 156, 935-949. <a href="https://doi.org/10.1016/j.cell.2014.02.001" target="_blank">https://doi.org/10.1016/j.cell.2014.02.001</a></p> | + | |
− | <p>Pacesa, M., Pelea, O., & Jinek, M. (2024). Past, present, and future of CRISPR genome editing technologies. <i>Cell</i>, 187, 1076-1100. <a href="https://doi.org/10.1016/j.cell.2024.01.042" target="_blank">https://doi.org/10.1016/j.cell.2024.01.042</a></p> | + | |
− | <p>Paul, B., & Montoya, G. (2020). CRISPR-Cas12a: Functional overview and applications. <i>Biomedical Journal</i>, 43, 8-17. <a href="https://doi.org/10.1016/j.bj.2019.10.005" target="_blank">https://doi.org/10.1016/j.bj.2019.10.005</a></p> | + | |
− | <p>Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. <i>Nature</i>, 507, 62-67. <a href="https://doi.org/10.1038/nature13011" target="_blank">https://doi.org/10.1038/nature13011</a></p> | + | |
− | <p>Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., Koonin, E. V., & Zhang, F. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. <i>Cell</i>, 163, 759-771. <a href="https://doi.org/10.1016/j.cell.2015.09.038" target="_blank">https://doi.org/10.1016/j.cell.2015.09.038</a></p> | + | |
− | </section> | + | |
</body> | </body> | ||
+ | |||
</html> | </html> |
Revision as of 02:24, 1 October 2024
fgRNA Entryvector MbCas12a-SpCas9
This part integrates the crRNA of MbCas12a (BBa_K5237206) and the sgRNA of SpCas9 (BBa_K5237209) into a single fusion guide RNA (fgRNA). The fgRNA is functional meaning that the MbCas12a (BBa_K5237000), SpCas9 (BBa_K5237002) and the Cas-Staple (BBa_K5237003) can utilize the fgRNA to target two loci simultaneously. The fgRNA also works with the catalyitcally inactive versions. We could show editing with the active version and induced proximity of to loci with the inactive version.
Contents
Next to the well-studied linear DNA sequence, the 3D spatial organization of DNA plays a crucial role in gene
regulation,
cell fate, disease development and more. However, the tools to precisely manipulate this genomic architecture
remain limited, rendering it challenging to explore the full potential of the
3D genome in synthetic biology. We - iGEM Team Heidelberg 2024 - have developed PICasSO, a powerful molecular
toolbox based on various DNA-binding proteins to address this issue.
The PICasSO part collection offers a comprehensive, modular platform for precise manipulation and re-programming of DNA-DNA interactions using protein staples in living cells, enabling researchers to recreate natural 3D genomic interactions, such as enhancer hijacking, or to design entirely new spatial architectures for gene regulation. Beyond its versatility, PICasSO includes robust assay systems to support the engineering, optimization, and testing of new staples, ensuring functionality in vitro and in vivo. We took special care to include parts crucial for testing every step of the cycle (design, build, test, learn) when engineering new parts.
At its heart, the PICasSO part collection consists of three categories.
(i) Our DNA-binding
proteins
include our
finalized enhancer hijacking Cas staple as well as half staples that can be used by scientists to compose entirely
new Cas staples in the future. We also include our Simple staples that serve as controls for successful stapling
and can be further engineered to create alternative, simpler and more compact staples.
(ii) As functional elements, we list additional parts that enhance the functionality of our Cas and
Basic staples. These
consist of
protease-cleavable peptide linkers and inteins that allow condition-specific, dynamic stapling in vivo.
Besides staple functionality, we also include the parts to enable the efficient delivery of PICasSO's constructs
with our
interkingdom conjugation system.
(iii) As the final category of our collection, we provide parts that support the use of our custom
readout
systems. These include components of our established FRET-based proximity assay system, enabling users to
confirm
accurate stapling. Additionally, we offer a complementary, application-oriented testing system for functional
readouts via a luciferase reporter, which allows for straightforward experimental simulation of enhancer hijacking
in mammalian cells.
The following table gives a comprehensive overview of all parts in our PICasSO toolbox. The highlighted parts showed
exceptional performance as described on our iGEM wiki and can serve as a reference. The other parts in
the
collection are versatile building blocks designed to provide future iGEMers with the flexibility to engineer their
own custom Cas staples, enabling further optimization and innovation.
Our part collection includes:
DNA-binding proteins: The building blocks for engineering of custom staples for DNA-DNA interactions with a modular system ensuring easy assembly. | ||
BBa_K5237000 | fgRNA Entry vector MbCas12a-SpCas9 | Entryvector for simple fgRNA cloning via SapI |
BBa_K5237001 | Staple subunit: dMbCas12a-Nucleoplasmin NLS | Staple subunit that can be combined with sgRNA or fgRNA and dCas9 to form a functional staple |
BBa_K5237002 | Staple subunit: SV40 NLS-dSpCas9-SV40 NLS | Staple subunit that can be combined witha sgRNA or fgRNA and dCas12avto form a functional staple |
BBa_K5237003 | Cas Staple: SV40 NLS-dMbCas12a-dSpCas9-Nucleoplasmin NLS | Functional Cas staple that can be combined with sgRNA or fgRNA to bring two DNA strands into close proximity |
BBa_K5237004 | Staple subunit: Oct1-DBD | Staple subunit that can be combined to form a functional staple, for example with TetR. Can also be combined with a fluorescent protein as part of the FRET proximity assay |
BBa_K5237005 | Staple subunit: TetR | Staple subunit that can be combined to form a functional staple, for example with Oct1. Can also be combined with a fluorescent protein as part of the FRET proximity assay |
BBa_K5237006 | Simple staple: TetR-Oct1 | Functional staple that can be used to bring two DNA strands in close proximity |
BBa_K5237007 | Staple subunit: GCN4 | Staple subunit that can be combined to form a functional staple, for example with rGCN4 |
BBa_K5237008 | Staple subunit: rGCN4 | Staple subunit that can be combined to form a functional staple, for example with rGCN4 |
BBa_K5237009 | Mini staple: bGCN4 | Assembled staple with minimal size that can be further engineered | Functional elements: Protease-cleavable peptide linkers and inteins are used to control and modify staples for further optimization for custom applications |
BBa_K5237010 | Cathepsin B-cleavable Linker: GFLG | Cathepsin B-cleavable peptide linker that can be used to combine two staple subunits to make responsive staples |
BBa_K5237011 | Cathepsin B Expression Cassette | Expression Cassette for the overexpression of cathepsin B |
BBa_K5237012 | Caged NpuN Intein | A caged NpuN split intein fragment that undergoes protein trans-splicing after protease activation. Can be used to create functionalized staples units |
BBa_K5237013 | Caged NpuC Intein | A caged NpuC split intein fragment that undergoes protein trans-splicing after protease activation. Can be used to create functionalized staples units |
BBa_K5237014 | fgRNA processing casette | Processing casette to produce multiple fgRNAs from one transcript, that can be used for multiplexed 3D genome reprograming |
BBa_K5237015 | Intimin anti-EGFR Nanobody | Interkindom conjugation between bacteria and mammalian cells, as alternative delivery tool for large constructs |
BBa_K4643003 | incP origin of transfer | Origin of transfer that can be cloned into the plasmid vector and used for conjugation as a means of delivery | Readout Systems: FRET and enhancer recruitment to measure proximity of stapled DNA in bacterial and mammalian living cells enabling swift testing and easy development for new systems |
BBa_K5237016 | FRET-Donor: mNeonGreen-Oct1 | FRET Donor-Fluorpohore fused to Oct1-DBD that binds to the Oct1 binding cassette. Can be used to visualize DNA-DNA proximity |
BBa_K5237017 | FRET-Acceptor: TetR-mScarlet-I | Acceptor part for the FRET assay binding the TetR binding cassette. Can be used to visualize DNA-DNA proximity |
BBa_K5237018 | Oct1 Binding Casette | DNA sequence containing 12 Oct1 binding motifs, compatible with various assays such as the FRET proximity assay |
BBa_K5237019 | TetR Binding Cassette | DNA sequence containing 12 Oct1 binding motifs, can be used for different assays such as the FRET proximity assay | BBa_K5237020 | Cathepsin B-Cleavable Trans-Activator: NLS-Gal4-GFLG-VP64 | Readout system that responds to protease activity. It was used to test cathepsin B-cleavable linker |
BBa_K5237021 | NLS-Gal4-VP64 | Trans-activating enhancer, that can be used to simulate enhancer hijacking | BBa_K5237022 | mCherry Expression Cassette: UAS, minimal Promotor, mCherry | Readout system for enhancer binding. It was used to test cathepsin B-cleavable linker |
BBa_K5237023 | Oct1 - 5x UAS binding casette | Oct1 and UAS binding cassette, that was used for the simulated enhancer hijacking assay |
BBa_K5237024 | TRE-minimal promoter- firefly luciferase | Contains Firefly luciferase controlled by a minimal promoter. It was used as a luminescence readout for simulated enhancer hijacking |
1. Sequence overview
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 339
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 571
Illegal SapI site found at 662
Illegal SapI.rc site found at 280
2. Usage and Biology
2.1 Discovery and Mechanism of CRISPR/Cas9
In 2012, Jinek et al. discovered the use of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system to induce double-strand breaks in DNA. Since then, the system has been well established as a tool for genome editing. The CRISPR/Cas system, which originates from the bacterial immune system, is constituted by a ribonucleoprotein complex. For class 1 CRISPR systems, the RNA is complexed by multiple Cas proteins, whereas class 2 systems consist of a singular protein and RNA. The class 2 type II system describes all ribonucleoprotein complexes with Cas9 (Pacesa et al., 2024). They include a CRISPR RNA (crRNA), which specifies the target with a 20 nucleotide (nt) spacer sequence, and a transactivating CRISPR RNA (tracrRNA), which induces the processing by the Cas protein (Jinek et al., 2012) (Fig. 2 A). Furthermore, a specific three nucleotide sequence (NGG) on the 3' end in the targeted DNA is needed for binding and cleavage. This is referred to as the protospacer adjacent motif (PAM) (Sternberg et al., 2014). The most commonly used Cas9 protein is SpCas9 or SpyCas9, which originates from Streptococcus pyogenes (Pacesa et al., 2024).
A significant enhancement of this system was the introduction of single guide RNA (sgRNA)s, which combine the functions of a tracrRNA and crRNA (Mali et al., 2013). Moreover, Cong (2013) established precise targeting of human endogenous loci by designing the 20 nt spacer sequence accordingly.
2.2 Differences between Cas9 and Cas12a
Over the following years, further CRISPR/Cas systems have been discovered, including the Cpf1 system, which has been classified as Cas12a since then (Zetsche et al., 2015). Cas12a forms a class 2 type V system with its RNA, that in comparison to the type II systems, only requires a crRNA for targeting and activation. Cas12a is capable of processing the precursor crRNA into crRNA independently, whereas Cas9 requires the RNase III enzyme and tracrRNA for this process (Paul and Montoya, 2020). This crRNA is often also referred to as a guide RNA (gRNA). However, the stem loop that is formed when binding the Cas protein is structurally distinct to the Cas9 gRNA and positioned on the 5' side of the crRNA (Fig. 2 B). Similarly, the PAM (TTTV) is also on the 5' side (Pacesa et al., 2024). Cas9 possesses RuvC and HNH domains that are catalytically active, each of which cleaves one of the DNA strands at the same site, resulting in the formation of blunt end cuts (Nishimasu et al., 2014). Cas12a possesses one RuvC-like domain that creates staggered cuts with overhangs that are about 5nt long (Paul and Montoya, 2020).
2.3 Dead Cas Proteins and their Application
Specific mutations of these domains result in catalytic inactivity and therefore allow for the creation of nickases that only cut one of the DNA strands, or completely inactive Cas proteins (Koonin et al., 2023) (Kleinstiver et al., 2019). These are referred to as dead Cas proteins or dCas9 and dCas12a. These Cas proteins can be used to activate (CRISPRa) or inhibit (CRISPRi) the expression of genes by fusing them to effector domains and targeting the respective gene with the spacer sequence (Kampmann, 2017). A common approach for CRISPRa involves fusing Cas9 with the transcriptional activator VP64 (Kampmann, 2017).
2.4 fgRNA and CHyMErA System
Kweon et al. (2017) further expanded the ways in which the CRISPR/Cas system could be used by introducing the concept of fusion guide RNA (fgRNA)s. By fusing the 3' end of a Cas12a gRNA to the 5' end of a Cas9 gRNA, the newly created fgRNA could be used by both proteins independently for either multiplex genome editing or transcriptional regulation and genome editing in parallel (Fig. 3). Similarly, this is also possible using the Cas Hybrid for Multiplexed Editing and screening Applications (CHyMErA) system (Gonatopoulos-Pournatzis et al., 2020). In this instance, the gRNAs of Cas12a and Cas9 are connected in the opposite direction (3' Cas9 gRNA to 5' Cas12a gRNA), allowing for Cas12a to process the RNA into individual units (Fig. 3). Amongst other things, this allows for the analysis of the interaction between different genes by targeting them simultaneously with the two distinct spacers (Aregger et al., 2021) (Fig. 3).
3. Assembly and part evolution
Building on insights of our fusion Cas engineering cycle and findings from Kweon (2017), fgRNAs were designed by
combining the sgRNA from SpCas9 with the crRNA from MbCas12a, specifically the 3'-end of the MbCas12a gRNA was
fused to the 5'-end of the SpCas9 gRNA. Via this approach the two spacer sequences are fused directly, ensuring a
minimal distance between the two DNA strands.This also facilitates efficient cloning of different spacer
sequences. Linking the crRNA and sgRNA comes with the advantage of easily multiplexing the system, while still
guaranteeing that specific pairs of genomic loci are connected. The entry vector includes a U6 promoter, the
MbCas12a scaffold, a bacterial promoter driving ccdB expression, and the SpCas9 scaffold. Successful spacer
integration leads to the removal of the ccdB gene, allowing bacterial growth to be used as an indicator for
cloning success.
An existing vector containing the U6 promoter and the MbCas12a scaffold was selected as the basis
for entry vector cloning. The vector and a ccdB-SpCas9 scaffold construct were PCR amplified and fitting overhangs
for SapI were introduced. Golden Gate assembly (GGA) with Esp3I was used to create the final plasmid. The
transformation was carried out in the ccdB-resistant XL1 BlueE. Coli strain.
The first goal after assembly was to prove the editing activity of both proteins using fgRNA. The genes VEGFA and FANCF were selected as targets for Cas12a and Cas9, each target was tested with each Cas protein. Editing efficiency will be analyzed with the T7 Endonuclease I (T7EI) assay. Controls will include crRNAs and sgRNAs as positive controls, and non-targeting guides as negative controls. Desired spacer sequences can be ordered as oligos, annealed, and cloned in via GGA utilizing SapI.
Table 1: A list of all the different spacers we cloned and tested within the fgRNA | |
VEGFA | ctaggaatattgaagggggc |
FANCF | ggcggggtccagttccggga |
CCR5 | tgacatcaattattatacat |
TetO (BBa_K5237019) | tctctatcactgatagggag |
Oct1-B (BBa_K5237018) | atgcaaatactgcactagtg |
We constructed a second entry vector incorporating an AsCas12a scaffold (5' taatttctactcttgtagat 3') instead of MbCas12a. The sequence of the AsCas12a scaffold, was the only modification in the composite part. This vector was tested on the loci VEGFA and FANCF to assess its functionality.
4. Results
4.1 Editing endogenous loci with fgRNAs
To prove that our fusion gRNAs still result in active ribonucleoproteins, a series of different fgRNAs were
created, each carrying spacers specific to the VEGFA and FANCF genes.HEK293-T cells were transfected with the
Cas
protein and gRNA constructs. The editing rate was tested 72h after transfection via a T7 endonuclease I
assay.
AsCas12a and SpCas9 were used. The AsCas12a spacer targets VEGFA, while the SpCas9 spacer targets FANCF. The
samples included standard single gRNAs with the corresponding Cas protein, the fgRNA with only one of the two
Cas
proteins and the fgRNA with both Cas proteins simultaneously (Fig. 5). The sgRNAs allowed for
the highest editing rates for both genes (45% for VEGFA and 15% for FANCF), while the editing rates for FANCF
were
consistently lower in all experiments. Importantly, targeting FANCF with fgRNAs resulted in noticeable editing
of
about 10%, with just the SpCas9 and both Cas proteins in the sample. For VEGFA, the AsCas12a only sample
resulted
in approximately 20% editing rate in combination with the fgRNA, while adding both Cas proteins led to
approximately 40%. These initial results confirmed our engineering approach proving efficient genome editing
with
fgRNAs.
4.2 Fusion Guide RNAs Allow for Editing Rates With Variant Cas Orthologs
To further evaluate the capabilities of the fgRNAs, we tested them in combination with different Cas12a orthologs. After some initial testing, we decided on using MbCas12a together with SpCas9, because we found AsCas12a to be less active in a dual luciferase assay when co-transfected with SpCas9 compared to MbCas12a (Fig. 6). Between these two co-transfections the SpCas9 editing has not been significantly different.
Additionally, to test if the differences in editing rates from the preliminary assay resulted from the targeted
loci or the different Cas orthologs, the spacers were tested in both arrangements. Once with Cas12a targeting
FANCF and SpCas9 targeting VEGFA and once vice versa. To better assess the impact that the utilization of a
fgRNA
has on the editing rates, the sgRNAs were tested separately and in one sample.
Having the sgRNA with single Cas
proteins in the same sample resulted in no clear difference in the editing rates (Fig. 7). The fusion of the
gRNAs resulted in a lower editing rate overall. While the editing for VEGFA
stayed at about 20% in all cases, the editing for FANCF dropped significantly. When targeting the same gene
under
the same conditions, the editing rates for MbCas12a were overall lower than the ones from SpCas9.
4.3 The Inclusion of a Linker Does Not Lower Editing Rates
To further assess the effect of the genomic locus on the editing rate, we included CCR5 as an additional gene target. For this assay, a fgRNA with a 20 nt long linker was included between the two spacers. The editing rate for VEGFA was again relatively consistent throughout the samples (Fig. 8). For CCR5, the editing rate with sgRNAs was approximately the same at about 30%. However, it dropped below 10% for the fgRNA. The addition of the 20 nt linker had no effect on the editing rates compared to no linker.
4.4 fgRNAs can be used for CRISPRa
To establish the foundation for their use as protein scaffolds, we identified the next step as demonstrating the use of fgRNAs for CRISPR activation. For this, we intend to recruit the transcriptional activator VP64 to a firefly luciferase gene to induce expression. The VP64 protein is attached to the catalytically inactive Cas9 protein, which is then guided by gRNAs to the luciferase gene. The gRNAs target a TetO sequence, which is positioned in front of the luciferase gene in multiple repeats. The firefly luciferase activity was then quantified as photon counts and normalized against Renilla luciferase, which is expressed on a separate plasmid under an ubiquitous promoter. In two biological replicates we saw similar Relative luciferase activity with fgRNA as a guide compared to a sgRNA (Fig. 9).
4.5 Stapling Two DNA Strands Together Using fgRNAs
After showing the general capability of the fgRNA
to work for editing and for CRISPR activation, the next step was to use it to staple two DNA loci together, and
thereby induce proximity between two separate functional elements. For this, an enhancer plasmid and a reporter
plasmid was used. The reporter plasmid has firefly luciferase behind several repeats of a Cas9 targeted
sequence.
The enhancer plasmid has a Gal4 binding site behind several repeats of a Cas12a targeted sequence. By
introducing
a fgRNA staple and a Gal4-VP64, expression of the luciferase is induced (Fig. 10, Panel A).
Different linker lengths were tested. Cells were again normalized against ubiquitous renilla expression.
Using no linker between the two spacers showed similar relative luciferase activity to the baseline control
(Fig. 10, Panel B). An extension of the linker from 20 nt up to 40 nt resulted in an increasingly higher
expression of the
reporter gene. These results suggest an extension of the linker might lead to better transactivation when
hijacking an enhancer/activator.
5. References
Aregger, M., Xing, K., & Gonatopoulos-Pournatzis, T. (2021). Application of CHyMErA Cas9-Cas12a combinatorial genome-editing platform for genetic interaction mapping and gene fragment deletion screening. Nature Protocols, 16, 4722-4765. https://doi.org/10.1038/s41596-021-00595-1
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339, 819-823. https://doi.org/10.1126/science.1231143
Gonatopoulos-Pournatzis, T., Aregger, M., Brown, K. R., Farhangmehr, S., Braunschweig, U., Ward, H. N., Ha, K. C. H., Weiss, A., Billmann, M., Durbic, T., Myers, C. L., Blencowe, B. J., & Moffat, J. (2020). Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9-Cas12a platform. Nature Biotechnology, 38, 638-648. https://doi.org/10.1038/s41587-020-0437-z
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816-821. https://doi.org/10.1126/science.1225829
Kampmann, M. (2017). CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. ACS Chemical Biology, 13, 406-416. https://doi.org/10.1021/acschembio.7b00657
Kleinstiver, B. P., Sousa, A. A., Walton, R. T., Tak, Y. E., Hsu, J. Y., Clement, K., Welch, M. M., Horng, J. E., Malagon-Lopez, J., Scarfò, I., Maus, M. V., Pinello, L., Aryee, M. J., & Joung, J. K. (2019). Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nature Biotechnology, 37, 276-282. https://doi.org/10.1038/s41587-018-0011-0
Koonin, E. V., Gootenberg, J. S., & Abudayyeh, O. O. (2023). Discovery of diverse CRISPR-Cas systems and expansion of the genome engineering toolbox. Biochemistry, 62, 3465-3487. https://doi.org/10.1021/acs.biochem.3c00159
Kweon, J., Jang, A.-H., Kim, D.-e., Yang, J. W., Yoon, M., Rim Shin, H., Kim, J.-S., & Kim, Y. (2017). Fusion guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1. Nature Communications, 8. https://doi.org/10.1038/s41467-017-01650-w
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science, 339, 823-826. https://doi.org/10.1126/science.1232033
Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell, 156, 935-949. https://doi.org/10.1016/j.cell.2014.02.001
Pacesa, M., Pelea, O., & Jinek, M. (2024). Past, present, and future of CRISPR genome editing technologies. Cell, 187, 1076-1100. https://doi.org/10.1016/j.cell.2024.01.042
Paul, B., & Montoya, G. (2020). CRISPR-Cas12a: Functional overview and applications. Biomedical Journal, 43, 8-17. https://doi.org/10.1016/j.bj.2019.10.005
Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature, 507, 62-67. https://doi.org/10.1038/nature13011
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., Koonin, E. V., & Zhang, F. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 163, 759-771. https://doi.org/10.1016/j.cell.2015.09.038